Bristol Myers Squibb is facing several questions about its mid-term future after it delayed sales projections for its new product portfolio, which includes Reblozyl and Abecma.
The Big Pharma company said Thursday in its third-quarter financial results that it now expects to achieve “at least $10 billion” in sales from these drugs in 2026. Bristol Myers previously forecast $10 billion to $13 billion in sales of these therapies in 2025. The delay comes as CEO Giovanni Caforio prepares to step down and hand the reins to current COO Chris Boerner on Nov. 1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.